Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
October 09 2020 - 7:46PM
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today
released details about its upcoming COVID-19 Pipeline Update call
and webcast on October 13th, 2020.
Title:
Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion
and Management Q&A Conference ID: 2066037
Date of call: 10/13/2020 Time of
call: 16:30 Eastern Time Expected
Duration: 60 minutes + questions (analysts and general
public)
For registered analysts and pre-certified
participants:
Toll Free
Number: (833) 665-0715
For other participants (webcast, with ability to
submit questions during the session):
https://edge.media-server.com/mmc/p/tun863t9
Management participants
will include:Dr. Henry Ji, Chairman and CEODr. Mark
Brunswick, SVP and Head of Regulatory and QualityDr. Robert Allen,
SVP, Antiviral and Oncolytic Immunotherapy DevelopmentDr. Mike
Royal, Chief Medical OfficerDr. Alexis Nahama, SVP of Corporate
Development
R&D Day
Agenda:
• Strategic Outlook (Dr.
Henry Ji)
• Therapeutic Pipeline – Clinical Stage
(Management)
- STI-1499 (neutralizing
antibody)
- STI-5656 (abivertinib)
• Therapeutic Pipeline – IND enabling
Stage (Management)
- STI-2020 (affinity matured STI-1499)
- STI-2099 (encoded plasmid DNA expressing STI-2020)
• Therapeutic Discovery
(Dr. Henry
Ji)
- Neutralizing antibody cocktail (COVI-SHIELD™)
- Bispecific Neutralizing antibodies
- STI-2030 (Salicyn-30)
- STI-4398 (COVIDTRAP™: ACE2 receptor decoy protein)
- STI-3333 (T-VIVA-19™: protein-based vaccine)
- I-Cell vaccine delivery platform
• Diagnostics (Management)
- COVI-TRACK™: IgG/IgM Antibody Test
- COVI-TRACE™: HP-LAMP Molecular Detection Test
- COVI-STIX™: Viral Antigen Test
The webcast will be available on the Sorrento Therapeutics’
website for 30 days at www.sorrentotherapeutics.com.
About Sorrento Therapeutics,
Inc.Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to treat cancers
and COVID-19. Sorrento's multimodal, multipronged approach to
fighting cancer is made possible by its extensive immuno-oncology
platforms, including key assets such as fully human antibodies
("G-MAB™ library"), clinical stage immuno-cellular therapies
("CAR-T", "DAR-T"), antibody-drug conjugates ("ADCs"), and clinical
stage oncolytic virus ("Seprehvir®", “Seprehvec™”). Sorrento is
also developing potential antiviral therapies and vaccines against
coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™,
COVI-GUARD™, COVI-SHIELD™, COVI-AMG™ and T-VIVA-19™; and diagnostic
test solutions, including COVI-TRACK™, COVI-STIX™ and
COVI-TRACE™.
Sorrento's commitment to life-enhancing
therapies for patients is also demonstrated by our effort to
advance a first-in-class (TRPV1 agonist) non-opioid pain management
small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine
topical system) 1.8% for the treatment of post-herpetic neuralgia.
RTX has completed a phase 1B trial for intractable pain associated
with cancer and a phase 1B trial in osteoarthritis patients.
ZTlido® was approved by the FDA on February 28, 2018.
For more information, visit
www.sorrentotherapeutics.com
Forward-Looking StatementsThis
press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc., under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include statements regarding Sorrento’s pipeline and
plans with respect to its strategic outlook and clinical and
pre-clinical COVID-19 programs, its COVID-19 therapeutic and
diagnostic product candidates and pipeline, and its proprietary
technology platforms. Risks and uncertainties that could cause our
actual results to differ materially and adversely from those
expressed in our forward-looking statements, include, but are not
limited to: risks related to Sorrento’s and its subsidiaries’,
affiliates’ and partners’ technologies and prospects and
collaborations, including, but not limited to clinical development
risks, including risks in the progress, timing, cost, and results
of clinical trials and product development programs; risk of
difficulties or delays in obtaining regulatory approvals; risks
that clinical study results may not meet any or all endpoints of a
clinical study and that any data generated from such studies may
not support a regulatory submission or approval; risks that prior
test, study and trial results may not be replicated in future
studies and trials; risks of manufacturing and supplying drug
product; risks related to leveraging the expertise of its
employees, subsidiaries, affiliates and partners to assist the
company in the execution of its therapeutic and diagnostic product
candidates’ strategies; risks related to the global impact of
COVID-19; and other risks that are described in Sorrento’s most
recent periodic reports filed with the Securities and Exchange
Commission, including Sorrento’s Annual Report on Form 10-K for the
year ended December 31, 2019, and subsequent Quarterly Reports on
Form 10-Q filed with the Securities and Exchange Commission,
including the risk factors set forth in those filings. Investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release, and we
undertake no obligation to update any forward-looking statement in
this press release except as required by law.
ContactAlexis Nahama, DVM (SVP
Corporate Development)Email:
mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered
trademarks of Sorrento Therapeutics, Inc.G-MAB™, COVI-GUARD™,
COVI-SHIELD™, COVI-AMG™, COVIDTRAP™, T-VIVA-19™, COVI-MAB™,
ACE-MAB™, COVI-TRACK™, COVI-STIX™ and COVI-TRACE™ are trademarks of
Sorrento Therapeutics, Inc.
ZTlido® is a trademark owned by Scilex
Pharmaceuticals Inc.All other trademarks are the property of their
respective owners. © 2020 Sorrento Therapeutics, Inc. All Rights
Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Sep 2023 to Sep 2024